Zobrazeno 41 - 50
of 294
pro vyhledávání: '"Jan Walewski"'
Autor:
Árpád Illés, Andres Forero-Torres, Sergey Alekseev, Anas Younes, Valeria Buccheri, Keenan Fenton, Pier Luigi Zinzani, Joseph M. Connors, Anna Sureda, Andrea Gallamini, Rachael Liu, Lena Specht, Jan Walewski, Ashish Gautam, Andrew Grigg, Tae Min Kim, Graham P. Collins, Indra Purevjal, David J. Straus
Publikováno v:
Straus, D, Collins, G, Walewski, J, Zinzani, P L, Grigg, A, Sureda, A, Illes, A, Kim, T M, Alekseev, S, Specht, L, Buccheri, V, Younes, A, Connors, J, Forero-Torres, A, Fenton, K, Gautam, A, Purevjal, I, Liu, R & Gallamini, A 2020, ' Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy ', Leukemia and Lymphoma, vol. 61, no. 12, pp. 2931-2938 . https://doi.org/10.1080/10428194.2020.1791846
We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHEL
Autor:
Maciej Krzakowski, Włodzimierz Olszewski, Paulina Wieszczy, Ernest Kuchar, Jan Walewski, Marc Arbyn, Joanna Didkowska, Mirosław Wielgoś, Andrzej Nowakowski, Kinga Miłosz, Michal F. Kaminski, Mariusz Bidziński, Maryla H. Turkot
Publikováno v:
European Journal of Cancer Prevention
In Poland, cervical cancer incidence and mortality still remain considerably higher than in Western European countries or North America. Recent data indicate decreasing trends in women younger than 60 years and stable trends in older women. In this a
Autor:
Jan Walewski
Publikováno v:
Journal of Investigative Medicine. 68:331-334
One of the first achievements of molecular biology in lymphoma science was a discovery of cell of origin (COO) classification around 20 years ago with defining activated B-cell like (ABC) and germinal center B-cell like subtypes of diffuse large B-ce
Autor:
Hervé Tilly, Gilles Salles, Wolfram Klapper, Stephan Stilgenbauer, Martin Dreyling, Christian Schmidt, Michael Unterhalt, Pierre Feugier, Eva Hoster, Christiane Pott, Josée M. Zijlstra, Lothar Kanz, Jan Walewski, Vincent Ribrag, Michal Szymczyk, Jeanette K. Doorduijn, Olivier Hermine, Marek Trneny, Christian H. Geisler, Florian Kaiser, Hanneke C. Kluin-Nelemans, Catherine Thieblemont
Publikováno v:
Journal of Clinical Oncology, 38(3), 248-256. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(3), 248-+. American Society of Clinical Oncology
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Geisler, C H, Trneny, M, Stilgenbauer, S, Kaiser, F, Doorduijn, J K, Salles, G, Szymczyk, M, Tilly, H, Kanz, L, Schmidt, C, Feugier, P, Thieblemont, C, Zijlstra, J M, Ribrag, V, Klapper, W, Pott, C, Unterhalt, M & Dreyling, M H 2020, ' Treatment of Older Patients With Mantle Cell Lymphoma (MCL) : Long-Term Follow-Up of the Randomized European MCL Elderly Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 3, pp. 248-256 . https://doi.org/10.1200/JCO.19.01294
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(3), 248-256. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(3), 248-+. American Society of Clinical Oncology
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Geisler, C H, Trneny, M, Stilgenbauer, S, Kaiser, F, Doorduijn, J K, Salles, G, Szymczyk, M, Tilly, H, Kanz, L, Schmidt, C, Feugier, P, Thieblemont, C, Zijlstra, J M, Ribrag, V, Klapper, W, Pott, C, Unterhalt, M & Dreyling, M H 2020, ' Treatment of Older Patients With Mantle Cell Lymphoma (MCL) : Long-Term Follow-Up of the Randomized European MCL Elderly Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 3, pp. 248-256 . https://doi.org/10.1200/JCO.19.01294
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(3), 248-256. American Society of Clinical Oncology
PURPOSE In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209 ), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy an
Autor:
Jasmine Zain, Robert Orlowski, Philippe Armand, Guilherme Fleury Perini, Arun Balakumaran, Jakub Svoboda, Jing Ouyang, Pier Luigi Zinzani, Pei-Hsuan Chen, Vincent Ribrag, Catherine Thieblemont, Vladimir Melnichenko, Gayane Tumyan, Azra H. Ligon, Gilles Salles, Margaret A. Shipp, Maria D Caballero, Muhit Ozcan, Beth Christian, Zafer Gulbas, Donna Neuberg, Jan Walewski, Robert A. Redd, Arkendu Chatterjee, Sanjay R. Patel, Sergio Portino, Scott J. Rodig, Kamal Bouabdallah, Laura Fogliatto
Publikováno v:
Journal of Clinical Oncology
Ann Transl Med
Ann Transl Med
PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpr
Autor:
Ewa Paszkiewicz-Kozik, Malgorzata Debowska, Natalia Jakacka, Martyna Kotarska, Marcin Szymanski, Kamil Wisniewski, Agnieszka Konska, Malgorzata Jarzembowska, Joanna Drozd-Sokolowska, Joanna Romejko-Jarosinska, Anna Szumera-Cieckiewicz, Grzegorz Rymkiewicz, Bogna Ziarkiewicz-Wroblewska, Ewa Lech-Maranda, Jan Walewski, Iwona Hus
Publikováno v:
Chemotherapy. 67(4)
Introduction: Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma with a favorable prognosis in the majority of patients. The induction treatment is still based on rituximab and chemotherapy, though new anti-CD20 antibody and
Autor:
Beata Jagielska, Monika Swiatek, Elzbieta Sarnowska, Agnieszka Tupalska, Tomasz J. Sarnowski, Katarzyna Blachnio, Natalia Zeber-Lubecka, Iga Jancewicz, Szymon Kubala, Joanna Szarkowska, Ewa Grabowska, Ryszard Konopiński, Paulina Oksinska, Sergiusz Markowicz, Janusz A. Siedlecki, Michal Mikula, Jan Walewski, Natalia Rusetska, Bianka Swiderska, Agata Malinowska, Malgorzata Stachowiak, Pawel Cwiek
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4148, p 4148 (2021)
Volume 13
Issue 16
Cancers, Vol 13, Iss 4148, p 4148 (2021)
Volume 13
Issue 16
Growing tumors avoid recognition and destruction by the immune system. During continuous stimulation of tumor-infiltrating lymphocytes (TILs) by tumors, TILs become functionally exhausted
thus, they become unable to kill tumor cells and to produ
thus, they become unable to kill tumor cells and to produ
Autor:
Agnieszka Szymczyk, Marek Hus, Waldemar Tomczak, Beata Ostrowska, Sebastian Rybski, Anna Dąbrowska-Iwanicka, Tomasz Wróbel, Magdalena Olszewska-Szopa, Jan Walewski, Joanna Romejko-Jarosinska, Katarzyna Domanska-Czyz
Publikováno v:
Leukemialymphoma. 62(12)
Castleman disease (CD) was first described in the 1954 by Benjamin Castleman as a rare nonmalignant lymphoproliferative disorder [1]. Multicentric CD (MCD) involves multiple regions of enlarged lym...
Autor:
Anna Sureda, M. André, Alessandro Rambaldi, S. Chauvie, S. Viviani, Emanuele Zucca, D. Rossi, Jan Walewski, Cédric Rossi, Alden A. Moccia, Andrea Riccardo Filippi, Andrea Gallamini, Michel Meignan, Jan Maciej Zaucha
Publikováno v:
Hematological Oncology. 39
Autor:
Stanley Cheung, H.P. Miskin, Tomasz Wróbel, Owen A. O'Connor, Krzysztof Giannopoulos, Wojciech Jurczak, C. K Yannakou, C.Y. Cheah, A. D Ricart, Nicholas Wickham, J. P. Tang, M. Lasica, Katharine L Lewis, Jan Walewski, Constantine S. Tam, E. Normant, M. Długosz-Danecka
Publikováno v:
Hematological Oncology. 39
Introduction: TG-1701 is a selective, covalent BTK inhibitor administered once daily (QD). Both the “U2” combination (anti-CD20 mAb ublituximab + the PI3Kδ-CK1ϵ inhibitor umbralisib) and BTK inhibition are highly active in treatment-naive (TN)